公开(公告)号：US11359008B2

公开(公告)日：2022-06-14

申请号：US16375661

申请日：2019-04-04

Applicant: University of Southern California

Inventor： Wei Li ,  David Woodley ,  Mei Chen ,  Divya Sahu ,  Hangming Dong ,  Mengchen Zou

IPC: C07K16/18 ,  A61K39/395 ,  C07K16/28 ,  C12N15/113 ,  C12N15/13

Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α.

公开(公告)号：US11261235B2

公开(公告)日：2022-03-01

申请号：US16891413

申请日：2020-06-03

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： Mei Chen ,  David Woodley

IPC: A61K38/39 ,  C07K14/78 ,  A61K31/70

Abstract: The present invention discloses a method for treating wounds and for accelerating the healing of wounds by administering an effective amount of a pharmaceutical composition containing type VII collagen protein, mini-C7 protein, variants thereof or any combinations thereof. The pharmaceutical composition may be administered through a variety of routes including intravenous injection, topical application, or oral ingestion. The method may further include administering a genetically modified fibroblast capable of expressing type VII collagen protein, miniC7 protein, variants thereof or small growth factors to achieve synergistic healing effect.

公开(公告)号：US20160053003A1

公开(公告)日：2016-02-25

申请号：US14932908

申请日：2015-11-04

Applicant: University of Southern California

Inventor： Wei Li ,  David Woodley ,  Mei Chen ,  Divya Sahu ,  Hangming Dong ,  Mengchen Zou

IPC: C07K16/18 ,  C12N15/113

CPC classification number: C07K16/18 ,  A61K39/39558 ,  C07K16/2857 ,  C07K2317/34 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2330/50

Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α.

Abstract translation: 本文描述了包括特异性结合Hsp90α的单克隆抗体的组合物及其用于治疗HIF-1a过表达癌症的方法。 在一些实施方案中，癌症是乳腺癌或肺癌。 单克隆抗体结合Hsp90α中的表位TKPIWTRNP或Hsp90α中的VKHFSVEGQ。

公开(公告)号：US10227394B2

公开(公告)日：2019-03-12

申请号：US15302453

申请日：2015-04-08

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： Mei Chen ,  David T. Woodley

IPC: A61K38/17 ,  A61K38/00 ,  C07K14/78 ,  A61K9/00 ,  A61K47/42

Abstract: Disclosed are compositions and methods for accelerating wound closure and preventing inhibiting or reducing scarring or fibrosis. The methods of the present invention include administering to a person in need thereof an effective amount of a pharmaceutical composition comprising collagen 7 and/or one or more functional fragments or variants thereof. The functional fragments generally comprise at least one of the nine Fibronectin Type III-like Region of the NC1 region of collagen 7.

公开(公告)号：US20190298809A1

公开(公告)日：2019-10-03

申请号：US16412192

申请日：2019-05-14

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA ,  PHOENIX TISSUE REPAIR, INC.

Inventor： Mei Chen ,  David Woodley ,  Mark de Souza

IPC: A61K38/39

Abstract: The present disclosure provides methods of treating epidermolysis bullosa, and/or preventing, preventing the progression of, or delaying the onset of one or more symptom associated with scarring, e.g., of blisters, in subjects with epidermolysis bullosa through chronic systemic administration of collagen 7.

公开(公告)号：US20190256575A1

公开(公告)日：2019-08-22

申请号：US16276474

申请日：2019-02-14

Applicant: University of Southern California

Inventor： Mei Chen ,  David T. Woodley

IPC: C07K14/78 ,  A61K47/42 ,  A61K9/00

Abstract: Disclosed are compositions arid methods for accelerating wound closure and preventing inhibiting or reducing scarring or fibrosis. The methods of the present invention include administering to a person in need thereof an effective amount of a pharmaceutical composition comprising collagen 7 and/or one: or snore functional fragments or variants thereof. The functional fragments generally comprise at last one of the nine Fibronectin Type III-like Region of the NC1 region of collagen 7.

公开(公告)号：US10273294B2

公开(公告)日：2019-04-30

申请号：US14932908

申请日：2015-11-04

Applicant: University of Southern California

Inventor： Wei Li ,  David Woodley ,  Mei Chen ,  Divya Sahu ,  Hangming Dong ,  Mengchen Zou

IPC: C07K16/18 ,  C07K16/28 ,  A61K39/395 ,  C12N15/113

Abstract: Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1α-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP (SEQ ID NO: 1) in Hsp90α or VKHFSVEGQ (SEQ ID NO: 2) in Hsp90α.

公开(公告)号：US20140199309A1

公开(公告)日：2014-07-17

申请号：US14225311

申请日：2014-03-25

Applicant: University of Southern California

Inventor： Wei Li ,  David T. Woodley ,  Mei Chen

IPC: C07K14/435 ,  C07K16/18

CPC classification number: C07K14/435 ,  A61K31/713 ,  A61K39/0005 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/76 ,  G01N33/57484 ,  G01N33/92 ,  G01N2333/70596 ,  G01N2500/10

Abstract: The invention provides methods for treating HIF-1α-overexpressing human tumors, inhibiting HIF-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the Hsp90α from the tumors.

Abstract translation: 本发明提供使用各种类型的针对肿瘤Hsp90α的抑制剂治疗HIF-1α-过表达人类肿瘤，抑制HIF-1α-过表达肿瘤浸润和预防肿瘤转移和/或促进肿瘤预防的方法。